Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biopharmaceutical company Amarin (AMRN 3.74%) has earned a respected four-star ranking.
With that in mind, let's take a closer look at Amarin and see what CAPS investors are saying about the stock right now.
Amarin facts
|
Headquarters (founded) |
Dublin (1989) |
|
Market Cap |
$1.3 billion |
|
Industry |
Biotechnology |
|
Trailing-12-Month EBITDA |
($93.0 million) |
|
Management |
Chairman/CEO Joseph Zakrzewski |
|
Trailing-12-Month Return on Equity |
(115.2%) |
|
Cash / Debt |
$215.1 million / $130.8 million |
|
Competitors |
Merck (MRK 1.23%) |
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 94% of the 317 members who have rated Amarin believe the stock will outperform the S&P 500 going forward.
Just yesterday, one of those Fools, Kebin008, succinctly summed up the bull case for our community:
[Vascepa] is an extremely valuable asset Amarin has. I remain bullish on this stock given the CEO Joe Z's background with acquisitions. It is difficult to value the company given the uncertainty surrounding NCE status. Given the extended delay from the FDA, I believe that NCE will be granted in the end. The FDA may just simply be looking for a way to grant Amarin this designation. Furthermore, I believe that the acquisition talks will progress in a much more progressive manner once NCE status has been decided. At the current price, Amarin has great upside potential with limited downside risks.
Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.
